. Author manuscript; available in PMC: 2021 May 4.

Published in final edited form as: Leukemia. 2020 Nov 4;35(2):360–376. doi: 10.1038/s41375-020-01066-4

Table 7.

Small molecule inhibitors of RNA-binding and modifying proteins

Function	Gene Name	Inhibitor	CAS#	References
*RNA editing*	ADAR1 JAK2 BCR-ABL	8-azaadenosine SAR302503 Dasatinib	10299-44-2 936091-26-8 302962-49-8	¹⁰
*RNA modification*	METTL3 METTL14	In development		reviewed in^{15, 35}
	FTO	CS1 (Bisantrene) CS2 (Brequinar)	78186-34-2 96187-53-0	²⁹
	FTO	FB23/FB23–2	2243736-45-8	³⁰
*RNA splicing*	SF3B1	Spliceostatins A-G Pladienolides A(E7107) Herboxidiene (GEX1A)	391611-36-2 445493-23-2 142861-00-5	reviewed in^{37, 45, 61}
	RBM39	E7820 Indisulam Tasisulam	289483-69-8 165668-41-7 519055-62-0	^{50, 63}
	PRMT1 (type I PRMTs)	GSK3368715 MS023 (pan type I PRMTs inh.)	1629013-22-4 1831110-54-3	^{64, 65}
	PRMT5	GSK3203591 (GSK591) GSK3326595	1616391-87-7 1616392-22-3	^{64, 65}
*Decapping*	DCPS	RG3039	1005504-62-0	⁵¹
*Nuclear export & translation*	XPO1/CRM1	Selinexor	1393477-72-9	reviewed in⁶⁸
*Nuclear export & translation*	eIF4E	Ribavirin	36791-04-5	reviewed in⁷²
*Oncofetal RBPs*	MSI2	Ro 08-2750 (Ro)	37854-59-4	⁸²
	LIN28	C1632 (C₁₅H₁₅N₅O)	108825-65-6	⁸⁹
	LIN28	TPEN, LI71		⁹¹
	IGF2BP1	BTYNB	304456-62-0	¹⁰⁰